Header Logo

Connection

RITSUKO KOMAKI to Antineoplastic Agents, Immunological

Back to Details
This is a "connection" page, showing publications RITSUKO KOMAKI has written about Antineoplastic Agents, Immunological.
RITSUKO KOMAKI
Connection Strength
0.087
Antineoplastic Agents, Immunological
  1. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
    View in: PubMed
    Score: 0.087
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.